Today, on Wednesday, the price of the Novo Nordisk share is able to significantly increase. The share increased to 168.82 euros on the Tradegate trading platform, a gain of more than 15%. As a result, Novo Nordisk is currently trading at a record high. The share has now more than doubled since the AKTIONR suggestion. Positive information about Wegovy is the cause of the tremendous rise today.
By reducing the risk of a catastrophic cardiovascular event, such as a stroke, by 20% in overweight or obese adults with a history of heart disease, Novo Nordisk said on Tuesday. This greatly beyond what was anticipated for the research.
To determine whether the weekly injection had any medical benefits, a sizable research named SELECT with 17,500 patients got underway nearly five years ago, according to the Reuters news agency.
Obese people are more likely to develop cardiovascular disease, but there are currently no authorized weight-management drugs that have been demonstrated to successfully manage weight while lowering the risk of heart attack, stroke, or cardiovascular mortality. Since semaglutide 2.4 mg lowers the risk of cardiovascular events, we are really happy with the SELECT study results, said Martin Holst Lange, Executive Vice President for Development at Novo Nordisk. Semaglutide 2.4 mg has the potential to alter how obesity is handled, according to the landmark research SELECT.
Deciding to purchase Novo Nordisk shares for 31.53 euros in March 2017 was advised by DER AKTIONR. Investors are now 435 percent in the black following today’s price increase. Even if there may be repeated instances of profit-taking in the meantime, Novo Nordisk’s long-term prospects remain positive. Investors let the gains accumulate.
Every investor wants to discover the next Tesla, Apple, Amazon, or Google before anybody else, add them to their portfolio, ignore them for years, and then declare ownership of the company when its value has increased tenfold, twentyfold, or even more. Or at least to identify the businesses whose stock has outperformed the overall market. “Stock picking” is the term of the skill involved in picking tomorrow’s winners. One of the most accomplished stock pickers currently working is Joel Tillinghast. He provides the reader with his ideas, his approaches, and his plans in this book. He demonstrates how to think, how to take advantage of market niches, how to avoid common blunders, and much more. The book is ultimately intended to help its readers become more successful capitalists.